Introduction

1. No. 079 Positron emission tomography-computed tomography (PET-CT) role in predicting mortality in patients with metastatic bladder cancer Nathan Lawrentschuk, M. Carme Mir, Nathan Papa, Ian Davis, Damien Bolton, Andrew Scott University of Melbourne, Department of Surgery Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg, Melbourne, Vic 3084 AUSTRALIA • Results • In all, 49% patients (n=48) had a PET-N positive study, the remainder (n=46) PET-N negative. • Groups were almost identical for clinical stage (based on transurethral biopsy, CT scan and clinical examination) and grade at the time of PET-CT. • PET status had no significant difference from date of diagnosis of UC to overall survival (OS). • However, on further analysis of survival after the first staging PET study, using a Cox regression and adjusting for age and gender, having a PET-M positive study had a HR = 1.86(CI 1.05-3.30) for OS (Figure 1). • The time to death of patients with a PET-M positive study appeared 86% quicker than if PET-M negative study. Further, those with a PET-M negative study had a 46% reduction in the rate of progression to death. • Finally, the timing of the PET from original diagnosis was not significantly different between groups indicating no lead or length bias with PET study results. Introduction 18F- fluorodeoxyglucose (18F-FDG)-PET has assisted in predicting therapeutic response and outcome in patients with various tumours. Aim Our aim was to investigate the correlation between 18F-FDG PET-CT metabolic uptake within tumour deposits and clinical outcomes in patients with metastatic urothelial carcinoma (UC) arising in the bladder. • Methods • A total of 94 patients • Biopsy-proven UC at a single centre • All underwent FDG-PET CT scans at the time of staging for metastatic disease. • Data on staging, mortality and surgery was de-identified and linked through the statewide prospective Victorian Cancer Registry database. • Patients were divided into :1) PET-nodal metastasis (PET-N) positive and 2) negative groups according to the presence or absence of FDG uptake on this original study**some had repeat and later studies but we focused on the initial staging study • Kaplan-Meier analysis was used to determine survival outcomes according to 18F-FDG-PET metabolic response Conclusions Uptake of 18F-FDG in metastatic UC is significantly associated with OS. This data may assist for prognosis and trial selection of patients with metastatic UC but should be confirmed in a multicentre trial. References Available on request. Acknowledgements We acknowledge the dedication and assistance of the staff in the PET-Centre Austin Hospital Melbourne Australia. Poster presentation sponsor